Browse > Article
http://dx.doi.org/10.15324/kjcls.2022.54.2.125

The Patterns of Conversion to Anti-Tuberculosis Drug Resistance in Mycobacterium tuberculosis  

Chong, Moo-Sang (Department of Clinical Laboratory Science, Cheju Halla University)
Lee, Kyutaeg (Department of Laboratory Medicine, Green Cross Laboratories)
Publication Information
Korean Journal of Clinical Laboratory Science / v.54, no.2, 2022 , pp. 125-132 More about this Journal
Abstract
The prevalence of multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB) are increasing. We analyzed the patterns of drug resistance and tracking period days of acquiring anti-mycobacterial resistance. From January 2010 to December 2019, drug susceptibility tests (DST) were performed by the absolute concentration method using the Löwenstein-Jensen solid medium and pyrazinamidase activity test (to assess pyrazinamide resistance) in samples from patients who were referred to the Green Cross Laboratories in Yongin. Among the cases that showed resistance to one or more anti-tuberculosis drugs, 55 patients (33.1%) were resistant to isoniazid (INH) at the time of initial referral, and the rates for the development of resistant anti-tuberculosis drugs were ethambutol (EMB) (26.6%), rifampicin (RFP) (21.9%), quinolones (QUI) (21.9%) and pyrazinamide (PZA) (10.9%), in that order. In the cases sensitive to all 10 anti-tuberculosis drugs initially, the development of resistance to INH was the most frequent, seen in 43 patients (7.2%). The average follow-up period was 435.6 days, and the resistance development was observed in the order of INH (7.2%), RFP (3.9%), SM (1.9%), QUI (0.7%), amikacin (AMK) (0.5%), and EMB (0.5%). The conversion of susceptible strains to resistant strains is an important warning sign for the patient, especially in cases of conversion to MDR or XDR. This information would be helpful for improving patient care during TB treatment.
Keywords
Anti-tuberculosis drug; Conversion to resistant; Drug susceptibility; Mycobacterium tuberculosis; Tuberculosis;
Citations & Related Records
Times Cited By KSCI : 1  (Citation Analysis)
연도 인용수 순위
1 GBD Tuberculosis Collaborators. The global burden of tuberculosis: results from the Global Burden of Disease Study 2015. Lancet Infect Dis. 2018;18:261-284. https://doi.org/10.1016/S1473-3099(17)30703-X   DOI
2 Korea Centers for Disease Control and Prevention. Korean guidelines for tuberculosis (4th edition). Seoul: Korea Centers for Disease Control and Prevention; 2020. p16-59.
3 Pablos-Mendez A, Raviglione MC, Laszlo A, Binkin N, Rieder HL, Bustreo F, et al. Global surveillance for antituberculosis-drug resistance, 1994-1997. World Health Organization-International Union against tuberculosis and lung disease working group on anti-tuberculosis drug resistance surveillance. N Engl J Med. 1998;338:1641-1649. http://doi.org/10.1056/NEJM199806043382301   DOI
4 Kim DH, Kim HJ, Park SK, Kong SJ, Kim YS, Kim TH. et al. Treatment outcomes and long-term survival in patients with extensively drug-resistant tuberculosis. Am J Respir Crit Care Med. 2008;178:1075-1082. https://doi.org/10.1164/rccm.200801-132OC   DOI
5 World Health Organizaton. Guidelines for the programmatic management of drug-resistant tuberulosis. Emergency update 2008. Geneva.World Health Organization; 2008.
6 Joint Committee for the Development of Korean Guideline for Tuberculosis; Korean Centers for Disease Control and Prevention. Korean guidelines for tuberculosis. 1st ed. Cheongwon: Korea Centers for Disease Control and Prevention; 2011.
7 Van Deun A, Maug AK, Salim MA, Das PK, Sarker MR, Daru P, et al. Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am J Respir Crit Care Med. 2010;182:684-692. https://doi.org/10.1164/rccm.201001-0077OC   DOI
8 Kim BJ, Lee IH, Lee DH, Bai GH, Kong SJ, Lee SH, et al. The Current Status of Multidrug-resistant Tuberculosis in Korea. Tuberc Respir Dis. 2006;60:404-411. https://doi.org/10.4046/trd.2006.60.4.404   DOI
9 World Health Organization. Global tuberculosis report 2018. Geneva. World Health Organization; 2018.
10 Centers for Disease Control and Prevention (CDC). Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs--worldwide, 2000-2004. MMWR Morb Mortal Wkly Rep. 2006;55:301-305. https://doi.org/10.1037/e566482006-002   DOI
11 Velayati AA, Masjedi MR, Farnia P, Tabarsi P, Ghanavi J, Ziazarifi AH, et al. Emergence of new forms of totally drug-resistant tuberculosis bacilli: super extensively drug-resistant tuberculosis or totally drug-resistant strains in iran. Chest. 2009;136:420-425. https://doi.org/10.1378/chest.08-2427   DOI
12 Espinal MA, Laszlo A, Simonsen L, Boulahbal F, Kim SJ, Reniero A, et al. Global trends in resistance to antituberculosis drugs. World Health Organization-International union against tuberculosis and lung disease working group on anti-tuberculosis drug resistance surveillance. N Engl J Med. 2001;344:1294-1303. http://doi.org/10.1056/NEJM200104263441706   DOI
13 Mitchison DA. Drug resistance in tuberculosis. Eur Respir J. 2005;25:376-379. https://doi.org/10.1183/09031936.05.00075704   DOI
14 World Health Organization. WHO treatment guidelines for drug-resistant tuberculosis. Geneva. World Health Organization; 2016.
15 Korea Centers for Disease Control and Prevention. Annual report on the notified tuberculosis patients in Korea 2019. Seoul: Korea Centers for Disease Control and Prevention; 2020. p35-41.
16 Lee KT, Chong MS. The patterns of acquiring anti-mycobacterial drug resistance by susceptible strains of Mycobacterium tuberculosis. Korean J Clin Lab Sci. 2021;53:137-142. https://doi.org/10.15324/kjcls.2021.53.2.137   DOI
17 Son EJ, Jeon DS. Current situation of tuberculosis and national strategic plan for tuberculosis control in Korea. J Korean Med Assoc. 2021;64:316-323. http://doi.org/10.5124/jkma.2021.64.4.316   DOI
18 Kang YA. Diagnosis and treatment of multidrug-resistant tuberculosis. J Korean Med Assoc. 2014;57:27-33. http://doi.org/10.5124/jkma.2014.57.1.27   DOI